NITO vs BIOA vs KYMR vs AMTX vs GEVO

For growth investors, Gevo, Inc.

(GEVO) is the stronger pick with 849. 3% revenue growth year-over-year, versus -100. 0% for N2OFF, Inc. (NITO). Analysts rate BioAge Labs, Inc. (BIOA) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -99. 8% for N2OFF, Inc. (NITO). Over 10 years, the gap is even starker: KYMR returned +154. 4% versus NITO's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.

(KYMR) is the lower-risk stock at 1. 15β versus Gevo, Inc. 's 1. 64β — meaning GEVO is approximately 43% more volatile than KYMR relative to the S&P 500. On balance sheet safety, BioAge Labs, Inc. (BIOA) carries a lower debt/equity ratio of 2% versus 36% for Gevo, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Gevo, Inc.

(GEVO) is pulling ahead at 849. 3% versus -100. 0% for N2OFF, Inc. (NITO). On earnings-per-share growth, the picture is similar: N2OFF, Inc. grew EPS 88. 5% year-over-year, compared to -23. 8% for Kymera Therapeutics, Inc.. Over a 3-year CAGR, GEVO leads at 415. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

N2OFF, Inc.

(NITO) is the more profitable company, earning 0. 0% net margin versus -896. 1% for BioAge Labs, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NITO leads at 0. 0% versus -1031. 5% for BIOA. At the gross margin level — before operating expenses — BIOA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Kymera Therapeutics, Inc.

(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Gevo, Inc. (GEVO) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +154. 4%, GEVO: -98. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (NITO (Basic Materials) and BIOA (Healthcare) and KYMR (Healthcare) and AMTX (Energy) and GEVO (Basic Materials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: NITO is a small-cap quality compounder stock; BIOA is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; AMTX is a small-cap quality compounder stock; GEVO is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.